PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsRintatolimod
Rintatolimod
Rintatolimod is an oligonucleotide pharmaceutical. It is currently being investigated in clinical studies.
Download report
Favorite
COVID-19
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
No data
Clinical
Clinical Trials
27 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
FatigueD005221R53.83112
Chronic fatigue syndromeD015673EFO_0004540G93.31112
SyndromeD013577112
MyalgiaD063806M79.111
EncephalomyelitisD004679EFO_000142311
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AdenocarcinomaD000230122
Hiv infectionsD015658EFO_0000764B2022
Hiv seropositivityD00667922
Pancreatic neoplasmsD010190EFO_0003860C25122
Ovarian neoplasmsD010051EFO_0003893C56222
Ovarian epithelial carcinomaD000077216222
Prostatic neoplasmsD011471C6111
Human influenzaD007251EFO_0007328J11.1111
DiseaseD004194EFO_0000408R6911
Post-acute covid-19 syndromeD00009402411
Show 3 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C5011
Triple negative breast neoplasmsD06472611
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameRintatolimod
INNrintatolimod
Description
Rintatolimod, sold under the tradename Ampligen, is a medication intended for treatment of myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS). There is some evidence it may improve some ME/CFS symptoms.
Classification
Oligonucleotide
Drug classimmunomodulators: immunomodulators, toll-like receptor agonists
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
Identifiers
PDB
CAS-ID38640-92-5
RxCUI
ChEMBL IDCHEMBL2107862
ChEBI ID
PubChem CID
DrugBank
UNII ID94325AJ25N (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 658 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
3 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use